InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
62,814.29
(
-0.60%
)
Post# of 253355
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120561
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 50568

Friday, 08/03/2007 12:59:48 PM

Friday, August 03, 2007 12:59:48 PM

Post# of 253355
AMGN has a poor track record in internal drug discovery. They don’t seem to attract the best scientists, who evidently prefer San Francisco and Boston to the San Fernando Valley (“Armpit of the Pacific”). I think AMGN is going to have a hard time replacing the revenue in the EPO and G-CSF franchises.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up